SELLAS receives FDA Fast Track for SLS009 in PTCL; raises $4M via registered direct offering

SELLAS Life Sciences Group, Inc.

FDA granted Fast Track Designation for SLS009 to treat relapsed/refractory Peripheral T-cell Lymphomas (PTCL).
SLS009 showed 36.4% overall response rate in Phase 1 PTCL patients vs 25.8% for standard of care belinostat.
Registered direct offering of 3,652,300 shares/warrants at $1.0952/share for ~$4M gross proceeds; closing expected Nov 2, 2023.
Existing warrants from April 2022 repriced to $0.9702 and extended to November 2, 2028.
A.G.P./Alliance Global Partners acting as lead placement agent; Maxim Group as co-placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners and Maxim Group LLC (effective 2023-10-30).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners and Maxim Group LLC
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, the Company entered into a placement agency agreement (the "Placement Agent Agreement") with A.G.P./Alliance Global Partners ("A.G.P.") and Maxim Group LLC ("Maxim", and together with A.G.P., the "Placement Agents") pursuant to which the Company engaged A.G.P. and Maxim as the exclusive placement agents in connection with the Offering.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Purchase Agreement valued at approximately $4.0 million (effective 2023-10-30).

Action: entry
Agreement: equity purchase
Value: approximately $4.0 million
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, SELLAS Life Sciences Group, Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") with a single institutional investor (the "Investor"), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the "Offering"), (i) an aggregate of 3,100,000 shares (the "Shares") of common stock, par value $0.0001 per share, of the Company ("Common Stock") and (ii) an aggregate of 552,300 pre-funded warrants exercisable for shares of Common Stock (the "Pre-Funded Warrants") to the Investor, together with common warrants ("Common Warrants") to purchase up to 3,652,300 shares of Common Stock.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-112759

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.